Drug
Gestodene/EE Patch (BAY86-5016)
Gestodene/EE Patch (BAY86-5016) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
20%
Ph phase_1
1
20%
Ph phase_2
3
60%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
NCT00910637
completedphase_2
Russia/Ukraine Suppression of Ovarian Activity Study
NCT02550977
completedphase_2
FC Patch Low: Metabolism Study
NCT00933179
completedphase_2
Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.
NCT01204190
completedphase_1
Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites
NCT01083264
Clinical Trials (5)
Showing 5 of 5 trials
NCT00910637Phase 3
Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles
NCT02550977Phase 2
Russia/Ukraine Suppression of Ovarian Activity Study
NCT00933179Phase 2
FC Patch Low: Metabolism Study
NCT01204190Phase 2
Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.
NCT01083264Phase 1
Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5